171 related articles for article (PubMed ID: 34319976)
21. Elimination of human onchocerciasis: history of progress and current feasibility using ivermectin (Mectizan(®)) monotherapy.
Cupp EW; Sauerbrey M; Richards F
Acta Trop; 2011 Sep; 120 Suppl 1():S100-8. PubMed ID: 20801094
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal.
Diawara L; Traoré MO; Badji A; Bissan Y; Doumbia K; Goita SF; Konaté L; Mounkoro K; Sarr MD; Seck AF; Toé L; Tourée S; Remme JH
PLoS Negl Trop Dis; 2009 Jul; 3(7):e497. PubMed ID: 19621091
[TBL] [Abstract][Full Text] [Related]
23. Onchocerciasis: shifting the target from control to elimination requires a new first-step-elimination mapping.
Rebollo MP; Zoure H; Ogoussan K; Sodahlon Y; Ottesen EA; Cantey PT
Int Health; 2018 Mar; 10(suppl_1):i14-i19. PubMed ID: 29471341
[TBL] [Abstract][Full Text] [Related]
24. Vector control and entomological capacity for onchocerciasis elimination.
Tirados I; Thomsen E; Worrall E; Koala L; Melachio TT; Basáñez MG
Trends Parasitol; 2022 Jul; 38(7):591-604. PubMed ID: 35379556
[TBL] [Abstract][Full Text] [Related]
25. Financial and Economic Costs of the Elimination and Eradication of Onchocerciasis (River Blindness) in Africa.
Kim YE; Sicuri E; Tediosi F
PLoS Negl Trop Dis; 2015; 9(9):e0004056. PubMed ID: 26360917
[TBL] [Abstract][Full Text] [Related]
26. How does onchocerciasis-related skin and eye disease in Africa depend on cumulative exposure to infection and mass treatment?
Vinkeles Melchers NVS; Stolk WA; Murdoch ME; Pedrique B; Kloek M; Bakker R; de Vlas SJ; Coffeng LE
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009489. PubMed ID: 34115752
[TBL] [Abstract][Full Text] [Related]
27. The impact of mass drug administration expansion to low onchocerciasis prevalence settings in case of connected villages.
de Vos AS; Stolk WA; Coffeng LE; de Vlas SJ
PLoS Negl Trop Dis; 2021 May; 15(5):e0009011. PubMed ID: 33979331
[TBL] [Abstract][Full Text] [Related]
28. Control of onchocerciasis in Africa: threshold shifts, breakpoints and rules for elimination.
Duerr HP; Raddatz G; Eichner M
Int J Parasitol; 2011 Apr; 41(5):581-9. PubMed ID: 21255577
[TBL] [Abstract][Full Text] [Related]
29. Impact of long-term treatment of onchocerciasis with ivermectin in Kaduna State, Nigeria: first evidence of the potential for elimination in the operational area of the African Programme for Onchocerciasis Control.
Tekle AH; Elhassan E; Isiyaku S; Amazigo UV; Bush S; Noma M; Cousens S; Abiose A; Remme JH
Parasit Vectors; 2012 Feb; 5():28. PubMed ID: 22313631
[TBL] [Abstract][Full Text] [Related]
30. The Interruption of Transmission of Human Onchocerciasis by an Annual Mass Drug Administration Program in Plateau and Nasarawa States, Nigeria.
Richards FO; Eigege A; Umaru J; Kahansim B; Adelamo S; Kadimbo J; Danboyi J; Mafuyai H; Saka Y; Noland GS; Anyaike C; Igbe M; Rakers L; Griswold E; Unnasch TR; Nwoke BEB; Miri E
Am J Trop Med Hyg; 2020 Mar; 102(3):582-592. PubMed ID: 32043442
[TBL] [Abstract][Full Text] [Related]
31. The geographic distribution of onchocerciasis in the 20 participating countries of the African Programme for Onchocerciasis Control: (1) priority areas for ivermectin treatment.
Noma M; Zouré HG; Tekle AH; Enyong PA; Nwoke BE; Remme JH
Parasit Vectors; 2014 Jul; 7():325. PubMed ID: 25053266
[TBL] [Abstract][Full Text] [Related]
32. Review of Ethiopian Onchocerciasis Elimination Programme.
Meribo K; Kebede B; Feleke SM; Mengistu B; Mulugeta A; Sileshi M; Samuel A; Deribe K; Tadesse Z
Ethiop Med J; 2017; 55(Suppl 1):55-63. PubMed ID: 28878430
[TBL] [Abstract][Full Text] [Related]
33. Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment.
Coffeng LE; Stolk WA; Hoerauf A; Habbema D; Bakker R; Hopkins AD; de Vlas SJ
PLoS One; 2014; 9(12):e115886. PubMed ID: 25545677
[TBL] [Abstract][Full Text] [Related]
34. Elimination of onchocerciasis from Colombia: first proof of concept of river blindness elimination in the world.
Nicholls RS; Duque S; Olaya LA; López MC; Sánchez SB; Morales AL; Palma GI
Parasit Vectors; 2018 Apr; 11(1):237. PubMed ID: 29642939
[TBL] [Abstract][Full Text] [Related]
35. Progress towards onchocerciasis elimination in Côte d'Ivoire: A geospatial modelling study.
Eneanya OA; Koudou BG; Aboulaye M; Elvis AA; Souleymane Y; Kouakou MM; Weil GJ; Fischer PU
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009091. PubMed ID: 33566805
[TBL] [Abstract][Full Text] [Related]
36. Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria.
Anagbogu IN; Saka YA; Surakat OA; Okoronkwo C; Davies E; Oyale P; Ekpo UF; Amazigo UV; Barbre K; Igbe M; Nyior A; Jacob SM; Gideon Nteun U; Abubakar Umar Z
Parasit Vectors; 2022 Jun; 15(1):201. PubMed ID: 35698164
[TBL] [Abstract][Full Text] [Related]
37. Onchocerca volvulus infection in Tihama region - west of Yemen: Continuing transmission in ivermectin-targeted endemic foci and unveiled endemicity in districts with previously unknown status.
Mahdy MAK; Abdul-Ghani R; Abdulrahman TAA; Al-Eryani SMA; Al-Mekhlafi AM; Alhaidari SAA; Azazy AA
PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006329. PubMed ID: 29505580
[TBL] [Abstract][Full Text] [Related]
38. Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in West Africa.
O'Hanlon SJ; Slater HC; Cheke RA; Boatin BA; Coffeng LE; Pion SD; Boussinesq M; Zouré HG; Stolk WA; Basáñez MG
PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004328. PubMed ID: 26771545
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of onchocerciasis in Africa and Yemen, 2000-2018: a geospatial analysis.
Schmidt CA; Cromwell EA; Hill E; Donkers KM; Schipp MF; Johnson KB; Pigott DM; ; Hay SI
BMC Med; 2022 Sep; 20(1):293. PubMed ID: 36068517
[TBL] [Abstract][Full Text] [Related]
40. Projected Number of People With Onchocerciasis-Loiasis Coinfection in Africa, 1995 to 2025.
Vinkeles Melchers NVS; Coffeng LE; Boussinesq M; Pedrique B; Pion SDS; Tekle AH; Zouré HGM; Wanji S; Remme JH; Stolk WA
Clin Infect Dis; 2020 May; 70(11):2281-2289. PubMed ID: 31304961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
